+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel



Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel



Bmc Cancer 18(1): 501



A computer-assisted diagnostic system for analyzing bone scans (BONENAVI) calculates the automated bone scan index (aBSI). Here we evaluated the aBSI as a prognostic imaging biomarker for men with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel. We retrospectively analyzed 48 patients who received cabazitaxel for mCRPC and evaluated the ability of the aBSI to predict overall survival (OS). The Cox proportional hazards model was used to investigate the associations between baseline aBSI at cabazitaxel treatment and OS with the clinical variables as follows: age, number of cycles of docetaxel, serum prostate-specific antigen, hemoglobin (Hb), lactate dehydrogenase (LDH), and alkaline phosphatase. We determined the C-index to evaluate the discriminatory ability of our models when we included or excluded the aBSI from the analyses. The median OS after cabazitaxel treatment was 10.0 months, and patients with aBSI ≤1% achieved significantly longer OS compared with patients with aBSI ≥1%. Multivariate analysis showed that age, Hb, LDH, and aBSI were independent prognostic factors of OS. Adding aBSI to the base model increased the C-index from 0.78 to 0.80. The aBSI may serve as a useful imaging biomarker for predicting OS among men with mCRPC treated with cabazitaxel. Prospective studies are required to establish the value of aBSI as prognostic imaging biomarker.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065438812

Download citation: RISBibTeXText

PMID: 29716525

DOI: 10.1186/s12885-018-4401-y


Related references

Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate. Clinical Genitourinary Cancer 15(4): 472-478, 2017

Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. Ejnmmi Research 6(1): 23, 2016

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncology 4(7): 944-951, 2018

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel. Oncotarget 8(63): 106468-106474, 2017

Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. Canadian Urological Association Journal 12(8): E365-E372, 2018

Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice. European Urology Focus 2(5): 540-546, 2016

Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer. Urologia Internationalis 99(4): 400-405, 2017

Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. Bju International 110(11 Pt B): E628-E634, 2012

Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. Journal of Clinical Oncology 30(5): 519-524, 2012

Complete radiologic response in metastatic castration-resistant prostate cancer treated with cabazitaxel. Iranian Journal of Medical Sciences 40(3): 294-296, 2015

Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel. Anticancer Research 38(7): 4179-4185, 2018

Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. Clinical Genitourinary Cancer 15(3): E429-E435, 2017

Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer. European Journal of Cancer 97: 41-48, 2018

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Lancet. Oncology 18(11): 1532-1542, 2017

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urologic Oncology 32(8): 1308-1316, 2014